Ymmunobio honored with 3rd place at the Prix Galien USA Awards

Friday, November 15, 2024 @ 10:00 am

Ymmunobio is proud to announce its recent recognition at the prestigious Prix Galien USA Awards, where the company achieved a 3rd-place honor. The Prix Galien Award acknowledges Ymmunobio’s dedication to advancing science and healthcare.

Held at the American Museum of Natural History in New York City, the awards celebrate innovation and excellence across the life sciences, with industry leaders from pharma, biotech, med tech, AI, and other sectors in attendance. Reflecting on the event, the Ymmunobio team shared a memorable conversation with a Prix Galien Foundation representative, who fondly recalled the unique pronunciation of “Ymmunobio,” demonstrating the company’s growing presence in the field.

In addition to the awards gala, Ymmunobio connected with industry pioneers, establishing new collaborations and fostering dialogue on emerging trends in healthcare technology and life sciences.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Pharvaris: 3rd quarter 2024 financial results and business updates

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses Intend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) Initiation of CHAPTER-3 global pivotal Phase 3 clinical study of deucrictibant for the
November 13, 2024

Aurealis Therapeutics: CHF 8M for chronic wounds studies and oncology program

Funds will be used to complete Phase 2 RCTs with AUP-16 for Chronic Wounds, and accelerate the development of AUP-55 for ovarian, peritoneal and bladder cancer.
November 13, 2024

Nouscom’s neoantigen immunotherapy with potential to ‘intercept’ cancer in Lynch Syndrome carriers

Lynch Syndrome (LS) is a common hereditary condition (affecting one in 300) conferring a high risk of developing colorectal, gastric, endometrial and other cancers NOUS-209 monotherapy is well tolerated and generates potent and long-lasting neoantigen-specific T cell responses Updated data to be presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
November 5, 2024

InSphero partners with Chayon in South Korea for in vitro technologies

InSphero, the pioneer in 3D cell culture and organ-on-chip technologies, today announced its distribution partnership with Chayon, a leading Seoul-based laboratory supplies provider. This partnership will bring InSphero’s reliable and scalable 3D in vitro solutions for drug development to South Korean researchers, further expanding the company’s global footprint.
November 4, 2024

LubioScience partners with Zymo Research for next-generation sequencing

LubioScience GmbH, Switzerland’s leading life science distributor, has partnered with Zymo Research to bring specialized Next-Generation Sequencing (NGS) services for epigenetics and microbiomics to the Swiss market. This collaboration enables Swiss biotech companies to obtain reliable NGS data with faster turnaround times and highly competitive pricing.
October 29, 2024